Accelerating Commercialization by a Drug Discovery Company
First written in FY2016. 4 of 7 entries say "Restated". Latest entry: FY2019-Q3.
No other company in this theme has enough history to compare yet.
- FY2019-Q3AdvancedAnnual report
「In nucleic acid therapeutics drug discovery, an siRNA formulation targeting KRAS-mutated cancers was authorized by the U.S. FDA (Food and Drug Administration) for clinical trial implementation and will proceed to a Phase 1 clinical trial.」
In the drug discovery business, the siRNA formulation for KRAS-mutated cancers obtained authorization from the U.S. FDA to conduct clinical trials, reaching the stage of proceeding to a Phase 1 trial. - FY2018RestatedAnnual report
「In the drug discovery business, the company is advancing research and development in the fields of fibrosis and refractory cancer treatments and will develop them into a new core business.」
The company has reaffirmed its policy of developing drug discovery in the fields of fibrosis and refractory cancers into a new core business. - FY2018-Q2RestatedAnnual report
「In the drug discovery business using nucleic acid therapeutics, research and development is continuing, centered on the base established on the U.S. West Coast last year, with the aim of creating products that will form the pipeline following the liver cirrhosis treatment.」
The company continues efforts to make drug discovery a new core business, centered on its base established on the U.S. West Coast. - FY2018-Q1RestatedAnnual report
「In the drug discovery business using nucleic acid therapeutics, resources are being invested to create products that will form the next pipeline following the liver cirrhosis treatment, which made significant progress last year.」
The company continues drug discovery using nucleic acid therapeutics and is investing resources in building a product pipeline following the liver cirrhosis treatment. - FY2017RestatedAnnual report
「For other treatments, including cancer treatments, the company will strengthen activities centered on Nitto BioPharma, Inc., which operates the drug discovery business, with the aim of making drug discovery a new core business for the group.」
The company has reaffirmed its policy of making drug discovery, including cancer treatments, a new core business centered on Nitto BioPharma. - FY2017-Q2AdvancedAnnual report
「In addition, in July of this year, the company began operating a drug discovery business in the United States targeting cancer and other intractable diseases.」
The company began operating a drug discovery business in the United States targeting intractable diseases. - FY2016First statedAnnual report
「In January 2016, the company established Nitto BioPharma, Inc., a new U.S. company dedicated to drug discovery. It will work to accelerate commercialization with support from regulatory authorities and provide products to patients as quickly as possible.」
The company established a dedicated drug discovery company in the United States and plans to advance commercialization with support from regulatory authorities.